RETRACTED: Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0286848 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift PLOS ONE, 2024. Verfasst von Magdi E A Zaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Department of Chemistry, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: COVID-19, Nervous System Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IM-SIU), Saudi Arabia.
Abstract (Originalsprache)
Several studies have revealed that SARS-CoV-2 damages brain function and produces significant neurological disability. The SARS-CoV-2 coronavirus, which causes COVID-19, may infect the heart, kidneys, and brain. Recent research suggests that monoamine oxidase B (MAO-B) may be involved in metabolomics variations in delirium-prone individuals and severe SARS-CoV-2 infection. In light of this situation, we have employed a variety of computational to develop suitable QSAR model using PyDescriptor and genetic algorithm-multilinear regression (GA-MLR) models (R 2 = 0.800–793, Q 2 LOO = 0.734–0.727, and so on) on the data set of 106 molecules whose anti-SARS-CoV-2 activity was empirically determined. QSAR models generated follow OECD standards and are predictive. QSAR model descriptors were also observed in x-ray-resolved structures. After developing a QSAR model, we did a QSAR-based virtual screening on an in-house database of 200 compounds and found a potential hit molecule. The new hit’s docking score (-8.208 kcal/mol) and P IC 50 (7.85 M) demonstrated a significant affinity for SARS-CoV-2’s main protease. Based on post-covid neurodegenerative episodes in Alzheimer’s and Parkinson’s-like disorders and MAO-B’s role in neurodegeneration, the initially disclosed hit for the SARS-CoV-2 main protease was repurposed against the MAO-B receptor using receptor-based molecular docking, which yielded a docking score of -12.0 kcal/mol. This shows that the compound that inhibits SARS-CoV-2’s primary protease may bind allosterically to the MAO-B receptor. We then did molecular dynamic simulations and MMGBSA tests to confirm molecular docking analyses and quantify binding free energy. The drug-receptor complex was stable during the 150-ns MD simulation. The first computational effort to show in-silico inhibition of SARS-CoV-2 Mpro and allosteric interaction of novel inhibitors with MAO-B in post-covid neurodegenerative symptoms and other disorders. The current study seeks a novel compound that inhibits SAR’s COV-2 Mpro and perhaps binds MAO-B allosterically. Thus, this study will enable scientists design a new SARS-CoV-2 Mpro that inhibits the MAO-B receptor to treat post-covid neurological illness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Department of Chemistry, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Tishk International University, Erbil, Kurdistan Region, Iraq.
- Department of Chemistry, Vidya Bharti Mahavidyalaya, Amravati, Maharashtra, India.
- Datta Meghe College of Pharmacy, DMIHER Deemed University, Wardha, India.
- Department of Chemical Technology, Dr Babasaheb Ambedkar Marathwada University, Aurangabad, India.
- Department of Pharmaceutics, P. E. S. Modern College of Pharmacy, Nigdi, Pune.
ORCID-Profile: Nikita Maruti Gaikwad, Rahul D Jawarkar
Förderung
- the Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IM-SIU), Saudi Arabia
Zitieren
APA
Zaki, M. E. A., Al-Hussain, S. A., Al-Mutairi, A. A., Samad, A., Masand, V. H., Ingle, R. G., Rathod, V. D., Gaikwad, N. M., Rashid, S., Khatale, P. N., Burakale, P. V., & Jawarkar, R. D. (2024). RETRACTED: Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder. PLOS ONE. https://doi.org/10.1371/journal.pone.0286848
Vancouver
Zaki MEA, Al-Hussain SA, Al-Mutairi AA, Samad A, Masand VH, Ingle RG, et al. RETRACTED: Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder. PLOS ONE. 2024. doi:10.1371/journal.pone.0286848
BibTeX
@article{Zaki2024,
author = {Zaki, Magdi E A and Al-Hussain, Sami A and Al-Mutairi, Aamal A and Samad, Abdul and Masand, Vijay H and Ingle, Rahul G and Rathod, Vivek Digamber and Gaikwad, Nikita Maruti and Rashid, Summya and Khatale, Pravin N and Burakale, Pramod V and Jawarkar, Rahul D},
title = {RETRACTED: Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0286848}
}
EUVIMED